Scott I did more research into TRPC drugs which have gone through phase 1 and the company that has developed TRPC inhibitors for receptors 4 and 5 last year recieved a 700 million AUD licence agreement on safety clearance and the potential for Karuna Pharmaceuticals to research and develop a drug for mood disorders. Tells you how big NYR will be and money pouring in on phase 1 results coming up. The Cardiovascular and stroke indication 2 in 1 mechanism of action where it protects heart and brain in one dose will be a game changer
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)